The swine flu outbreak is likely to benefit one of the most prolific and successful venture capital firms in the United States: Kleiner Perkins Caufield & Byers, Thomson Reuters Private Equity Week reported on Friday.
Shares of the two public companies in the firm's portfolio of eight Pandemic and Bio Defense companies -- BioCryst Pharmaceuticals (BCRX.O) and Novavax (NVAX.O) -- jumped Friday on news that the swine flu killed a reported 60 people in Mexico and has infected people in the United States.
The World Health Organization said the virus appears to be susceptible to Roche's (ROG.VX) flu drug Tamiflu, also known as oseltamivir, but not to older flu drugs such as amantadine.
No comments:
Post a Comment